Restasis For Your Precious Eyes

In this world of Computers there arise a problem for humans, the most common problems are related to eyes, dryness of eyes etc. Medical science has done much research to cure those effects and the name Restasis came into picture, chemically known as “cyclosporine ophthalmic emulsion”

Restasis® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

It was invented by Dr. Renee Kaswan, DVM, MS - Diplomate, American College of Veterinary Ophthalmologists, University of Georgia

Let’s have a look on its specifications
Important Safety Information: RESTASIS® Ophthalmic Emulsion should not be used by patients with active eye infections and has not been studied in patients with a history of herpes viral infections of the eye. RESTASIS® should not be used while wearing contact lenses. If contact lenses are worn, they should be removed prior to use. The most common side effect is a temporary burning sensation. Other side effects include eye redness, discharge, watery eyes, eye pain, foreign body sensation, itching, stinging, and blurred vision.

Nursing Mothers: Cyclosporine is known to be excreted in human milk following systemic administration but excretion in human milk after topical treatment has not been investigated. Although blood concentrations are undetectable after topical administration ofRestasis® ophthalmic emulsion, caution should be exercised whenRestasis® is administered to a nursing woman.

Pediatric Use: The safety and efficacy ofRestasis® ophthalmic emulsion have not been established in pediatric patients below the age of 16.

Geriatric Use: No overall difference in safety or effectiveness has been observed between elderly and younger patients.
Adverse Reactions: The most common adverse event following the use ofRestasis® was ocular burning (17%). Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Dosage And Administration: Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using. Instill one drop ofRestasis® ophthalmic emulsion twice a day in each eye approximately 12 hours apart.Restasis® can be used concomitantly with artificial tears, allowing a 15 minute interval between products. Discard vial immediately after use.

SUPPLY: Restasis® ophthalmic emulsion is packaged in single use vials. Each vial contains 0.4 mL fill in a 0.9 mL LDPE vial; 32 vials are packaged in a polypropylene tray with an aluminum peel able lid. The entire contents of this tray (32 vials) must be dispensed as one unit.